ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

12:43 EDT 15 May 2018 | Nature Publishing

More From BioPortfolio on "ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors"